• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medtronic issues voluntary recall for certain In.Pact drug-coated balloon catheters

March 31, 2022 By Sean Whooley

Medtronic logo updatedMedtronic (NYSE:MDT) announced today that it voluntarily recalled a subset of its In.Pact Admiral and In.Pact AV balloon catheters.

The company initiated the recent recall of the paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheters due to the potential for pouch damage resulting in a loss of sterility.

According to the company, approximately 6,000 In.Pact Admiral catheters and three In.Pact AV catheters distributed to customers globally are impacted by the recall. To date, the company has received zero complaints involving the issue and there have been zero reports of injury or death related to the issue.

Medtronic discovered pouch damage during a routine inspection. Further investigation found that a change implemented to one manufacturing line was the cause. All batches manufactured on the line after the change are being retrieved and the issue on that line has been fixed, the company said. Additionally, to ensure further issues don’t arise, Medtronic paused production on all lines until a follow-up packaging inspection was completed and no additional errors were discovered.

There are no actions required for patients for whom the affected In.Pact Admiral and In.Pact AV drug-coated balloon catheters were used during a procedure. Medtronic said it is communicating to customers with affected product on hand to immediately quarantine and return the product and a signed confirmation form.

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Recalls, Vascular Tagged With: Medtronic

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS